Avigen is focused on acquiring, developing, and commercializing innovative therapeutics to treat serious neurological disorders, including neuropathic pain. Our goal is to develop and commercialize traditional pharmaceutical and biologics products, primarily small molecules.

Avigen is currently developing four candidates: AV650, AV411, AV333, and AV513:

In-Licensing Opportunities
The extensive experience of our senior management team with CNS small molecule development and commercialization, along with our current financial resources and status as a public company, put Avigen in a unique position to attract and acquire promising drug candidates to build its product pipeline.